Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
CNY8.56
+0.19 (+2.27%)
CN SHH Healthcare Biotechnology
Address
No. 5 Donghai Fourth Lane 317016
Linhai, CN
Linhai, CN
CEO
Zhiguo Zheng
Website
ausunpharm.com
IPO
2017-05-09
ISIN CNE100002XK2
Description
Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate compounds for drug synthesis. Its comprehensive portfolio includes fluorine-based compounds, prostaglandins, and anti-infectives, in addition to critical oncology therapeutics. The company also provides medications targeting liver, respiratory, cardiovascular, and cerebrovascular conditions, as well as central nervous system (CNS) disorders. Furthermore, Zhejiang Ausun Pharmaceutical is involved in contract processing services and continuous scientific research and development initiatives.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY8.56
+0.19 (+2.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
-0.21
Float Shares
818.99M
Free Float %
98.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.55% | -5.37% | -3.26% | -2.16% | -3.55% | -4.13% | +5.08% | -17.23% | -10.70% | +289.75% | +289.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8.56
DCF (Unlevered)
3.91
-54.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.26
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-1.1% Q1'26: +0.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-36.0% Q1'26: -14.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.6% Q1'26: -19.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+14.3% ★ Q1'26: +40.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+6.8% ★ Q1'26: +25.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: -3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.89× ★ Q1'26: 1.18× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
240.19M
est: 234.00M (+2.6%)
|
243.89M
est: 295.00M (-17.3%)
|
307.91M
est: 377.00M (-18.3%)
|
409.25M
est: 570.00M (-28.2%)
|
569.70M
est: 822.00M (-30.7%)
|
764.55M
est: 925.00M (-17.3%)
|
816.77M
est: 907.00M (-9.9%)
|
795.29M
est: 865.00M (-8.1%)
|
786.77M
est: 1.01B (-21.9%)
|
1.25B
1.25B – 1.25B
+23.7% YoY
|
1.25B
1.25B – 1.25B
+0.0% YoY
|
| EBITDA |
87.56M
est: 75.95M (+15.3%)
|
43.69M
est: 95.74M (-54.4%)
|
66.94M
est: 122.36M (-45.3%)
|
134.32M
est: 185.00M (-27.4%)
|
182.22M
est: 266.79M (-31.7%)
|
239.68M
est: 300.22M (-20.2%)
|
285.14M
est: 294.37M (-3.1%)
|
248.24M
est: 265.08M (-6.4%)
|
186.99M
est: 308.91M (-39.5%)
|
382.15M
382.15M – 382.15M
+23.7% YoY
|
382.15M
382.15M – 382.15M
+0.0% YoY
|
| EBIT |
69.69M
est: 62.46M (+11.6%)
|
22.98M
est: 78.74M (-70.8%)
|
44.21M
est: 100.62M (-56.1%)
|
108.89M
est: 152.14M (-28.4%)
|
152.20M
est: 219.40M (-30.6%)
|
205.20M
est: 246.89M (-16.9%)
|
244.54M
est: 242.09M (+1.0%)
|
185.71M
est: 209.65M (-11.4%)
|
112.80M
est: 244.31M (-53.8%)
|
302.23M
302.23M – 302.23M
+23.7% YoY
|
302.23M
302.23M – 302.23M
+0.0% YoY
|
| Net Income |
53.01M
est: 69.98M (-24.2%)
|
43.86M
est: 86.12M (-49.1%)
|
56.39M
est: 109.45M (-48.5%)
|
86.84M
est: 153.74M (-43.5%)
|
145.93M
est: 244.77M (-40.4%)
|
235.38M
est: 307.23M (-23.4%)
|
253.90M
est: 397.04M (-36.1%)
|
206.79M
est: 231.81M (-10.8%)
|
130.57M
est: 273.20M (-52.2%)
|
331.15M
331.15M – 331.15M
+21.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
40.21M
est: 35.01M (+14.9%)
|
45.86M
est: 44.13M (+3.9%)
|
57.84M
est: 56.40M (+2.5%)
|
63.71M
est: 85.27M (-25.3%)
|
81.25M
est: 122.97M (-33.9%)
|
114.55M
est: 138.38M (-17.2%)
|
118.41M
est: 135.69M (-12.7%)
|
123.21M
est: 125.82M (-2.1%)
|
106.15M
est: 146.61M (-27.6%)
|
181.38M
181.38M – 181.38M
+23.7% YoY
|
181.38M
181.38M – 181.38M
+0.0% YoY
|
| EPS |
0.11
est: 0.08 (+30.0%)
|
0.08
est: 0.10 (-20.0%)
|
0.11
est: 0.13 (-16.9%)
|
0.17
est: 0.19 (-8.5%)
|
0.26
est: 0.30 (-12.1%)
|
0.42
est: 0.37 (+13.1%)
|
0.31
est: 0.48 (-35.4%)
|
0.25
est: 0.28 (-10.7%)
|
0.16
est: 0.33 (-51.5%)
|
0.40
0.40 – 0.40
+21.2% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
18.23M
OE per share TTM
0.02
Owner's Yield
0.23%
Maintenance CapEx ratio
23.61%
Maint CapEx / Avg PPE
118.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 284.2K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 70.7K | 0.29% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 66.1K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.8K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.2K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.03M | 0.06% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.2K | 0.10% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.11M | 0.05% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 18.5K | 0.28% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 107.5K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
96.1K
Shares Outstanding
830.30M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ding Min Zhu | Chief Financial Officer | — | female |
| Huadong Zhang | Deputy GM & Director | — | male |
| Kai Gao | Deputy General Manager | — | male |
| Shilan Zheng | Accounting Supervisor & Director | — | female |
| Xiaochen Ying | Board Secretary | — | male |
| Yu Zhong | Deputy General Manager | — | female |
| Zhiguo Zheng | Chairman & GM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603229.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
